the aid library

LIST OPTIONS

Filter

3395

World Report on Vision

World Health Organization WHO (2019) C_WHO

At present at least 2.2 billion people around the world have a vision impairment, of whom at least 1 billion have a vision impairment that could have been prevented or is yet to be addressed. The world faces considerable challenges in terms of eye care, including inequalities in the coverage and qua... more

Download (297)

View PDF (318)

Neisseria gonorrhoeae Antimicrobial Resistance Surveillance: Consolidated Guidance

World Health Organization WHO (2020) C_WHO

Prevention, early diagnosis, and effective treatment are essential for the control and elimination of Neisseria gonorrhoeae as a public health problem. Currently, in Latin America and the Caribbean, treatment for gonorrhea infection is largely empiric and based on clinical diagnosis. In the Americas... more

Download (220)

View PDF (260)

Dangerous inequalities: World Aids report 2022

UNAIDS (2022) C_WHO

The world is not on track to end the AIDS pandemic. New infections are rising and AIDS deaths are continuing in too many communities. This report reveals why: inequalities are holding us back. In frank terms, the report calls the world’s attention to the painful reality that dangerous inequalities... more

External Link

Geographical, landscape and host associations of Trypanosoma cruzi DTUs and lineages

Izeta-Alberdi, A.; Ibarra-Cerdena, C.; Moo-llanes, D.; Ramsey,J. BMC Part of Springer Nature (2016) CC

Trypanosoma cruzi is the etiological agent of Chagas disease (CD), considered one of the most important parasitic infections in Latin America. Between 25 and 90 million humans are at infection risk via at least one of multiple infection mechanisms. Under natural conditions, the principal transmissio... more

Download (86)

View PDF (89)

Time to align: development cooperation for the prevention and control of non-communicable diseases

Collins, T.E.; Nugent, R.; Webb, D.; et al. The British Medical Journal (BMJ) (2019) CC2

The article "Time to Align: Development Cooperation for the Prevention and Control of Non-Communicable Diseases" argues for greater international cooperation and investment in addressing non-communicable diseases (NCDs), especially in low- and middle-income countries. Traditionally, global health fu... more

Download (228)

View PDF (255)

Transgender people and HIV

D. Adams; J. Byrne; M. Cabra; et al. World Health Organization (2015) C_WHO

Policy Brief

Download (253)

View PDF (256)

Health Professions' Speciality Training Guidelines for Zambia

Ministry of Health, Zambia (2017) C1

STP Guidelines, First Edition 2017

Download (183)

View PDF (206)

Towards transformative integration of the HIV and AIDS response into universal health coverage: Building on the strengths and successes of the HIV and AIDS response

G. Ooms; K. Kruja; M. Hart; D. Ruiz Aidsfonds; PITCH (Partnership to Inspire, Transform and Connect the HIV response) (2019) C2

Experiences from Indonesia, Kenya, Uganda and Ukraine

Download (156)

View PDF (225)

Practice Education in Nursing

Registered Nurses’ Association of Ontario (RNAO) (2016) CC

The purpose of this Guideline is to provide evidence-based recommendations that promote and sustain the undergraduate nursing student’s application of knowledge to practice in a variety of clinical learning environments. The Guideline explores the relationships among and between students and nursi... more

Download (185)

View PDF (246)

Country overview: Georgia

J.D. Javakhishvili; L. Sturua; I. Kirtadze; et al. European Monitoring Centre for Drugs and Drug Addiction (2015) C2

Download (141)

View PDF (194)

Universal Periodic Review of Albania - 33rd Session

Albania Center for Population and Development (ACPD); Albanian Association of People Living with HIVAIS; Roma Active Albania; STOP AIDS; Aksion Plus; et al. (2019) C2

Joint Stakeholder Submission Accessed: 29.09.2019

Download (222)

View PDF (249)

South-East Asia Regional Action Plan on Programmatic Management of Latent Tuberculosis Infection

World Health Organization (WHO), Regional Office for South-East Asia (2020) C_WHO

Download (264)

View PDF (274)

Multi-Professional Patient Safety Curriculum Guide

World Health Organization WHO (2011) C_WHO

The Multi-professional Patient Safety Curriculum Guide (2011) was developed to assist in the teaching of patient safety in universities and schools in the fields of dentistry, medicine, midwifery, nursing and pharmacy. It also supports the on-going training of all health care professionals. The C... more

Download (102)

View PDF (106)

Breast and cervical cancer screening services in Malawi: a systematic review

Pittalis, C.; Panteli, E.; Schouten, E. et al. BMC (2020) CC2

To identify and to assess factors enhancing or hindering the delivery of breast and cervical cancer screening services in Malawi with regard to accessibility, uptake, acceptability and effectiveness. Systematic review of published scientific evidence. A search of six bibliographic databases and gre... more

Download (760)

View PDF (1569)

Guidance on oral pre-exposure prophylaxis (PrEP) for serodiscordant couples, men and transgender women who have sex with men at high risk of HIV: recommendations for use in the context of demonstratio

World Health Organization (2012)

Download (345)

View PDF (456)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (212)

View PDF (170)

Checklist for assessing quality of healthcare - Hospitals

Kenya Ministry of Health (2021) C1

Kenya Quality Model for Health - Hospitals

Download (703)

View PDF (886)

Ghana National Health Insurance Scheme Improving Financial Sustainability Based on Expenditure Review

Huihui Wang, Nathaniel Otoo, and Lydia Dsane-Selby World Bank Group (2017) C1

Download (264)

View PDF (637)

Relevance of CBR and Inclusive Development in Post 2015 Agenda

Thomas, M. and Ninomiya, A. CBR Asia-Pacific Network (2015) C1

Download (388)

View PDF (591)

Guidelines on second-and third-line medicines and type of insulin for the control of blood glucose levels in non-pregnant adults with diabetes mellitus

World Health Organization WHO (2018) C_WHO

The new guidelines provide public health guidance on pharmacological agents for managing hyperglycaemia in type 1 and type 2 diabetes for use in primary health-care in low-resource settings. These guidelines update the recommendations for managing hyperglycaemia in the WHO Package of Essential NCD I... more